Golden State Wealth Management’s NovoCure NVCR Stock Holding History

Golden State Wealth Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$45	Hold	3	–	–	﹤0.01%	1596
2026 Q1	$33	Hold	3	–	–	﹤0.01%	1586
2025 Q4	$39	Hold	3	–	–	﹤0.01%	1656
2025 Q3	$39	Hold	3	–	–	﹤0.01%	1645
2025 Q2	$53	Hold	3	–	–	﹤0.01%	1557
2025 Q1	$53	Hold	3	–	–	﹤0.01%	1575
2024 Q4	$89	Buy	+3	New	+$63	﹤0.01%	1487
2021 Q1	–	Sell	-1,406	Closed	-$243K	–	225
2020 Q4	$243K	Buy	1,406 +6	+0.4%	+$821	0.07%	206
2020 Q3	$156K	Buy	+1,400	New	+$112K	0.05%	214
2020 Q2	–	Sell	-2,800	Closed	-$189K	–	703
2020 Q1	$189K	Buy	+2,800	New	+$221K	0.08%	161
2019 Q2	–	Sell	-400	Closed	-$19K	–	1133
2019 Q1	$19K	Buy	+400	New	+$19.3K	0.01%	642

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Golden State Wealth Management's NVCR Position: Q2 2026 in Review

Golden State Wealth Management held its NovoCure (NVCR) position steady in Q2 2026 at 3 shares worth $45. The position accounts for ﹤0.01% of the portfolio, ranked #1596.

Golden State Wealth Management first reported a position in NVCR in Q1 2019 and has held it in 11 quarters since. The position peaked at $243K in Q4 2020. 218 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

Golden State Wealth Management held 3 shares of NovoCure worth $45 as of Q2 2026.
Golden State Wealth Management left its NovoCure share count unchanged in Q2 2026.
NovoCure made up ﹤0.01% of Golden State Wealth Management's portfolio in Q2 2026, its #1596 holding.
Golden State Wealth Management first reported a position in NovoCure in Q1 2019 and has held it in 11 quarters since.
Golden State Wealth Management's NovoCure position peaked at $243K in Q4 2020.
218 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Golden State Wealth Management's 13F filing for Q2 2026, filed 22 Jul 2026.